Last reviewed 2026-05-14 · How we verify

Pyrocat (DIPYROCETYL)

Phase 2 active Small molecule

Pyrocat (generic name: DIPYROCETYL) is a dipyrocetyl drug. It is currently in Phase 2 development.

Pyrocat works by interacting with a specific molecular target to produce its therapeutic effect.

Pyrocat, also known as dipyrocetyl, is a small molecule drug of unknown target and class. Its commercial status is unclear, and it is not known whether it is FDA-approved or off-patent. The indications for Pyrocat are also unknown. As a result, there is limited information available on its safety profile and pharmacokinetics. Further research is needed to fully understand this compound.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIPYROCETYL
Drug class	dipyrocetyl
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Pyrocat is a key that fits into one of those locks. When it binds to the lock, it triggers a series of chemical reactions that help to treat a particular condition. This process is called a pharmacological response.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pyrocat CI brief — competitive landscape report
Pyrocat updates RSS · CI watch RSS

Frequently asked questions about Pyrocat

What is Pyrocat?

Pyrocat (DIPYROCETYL) is a dipyrocetyl drug.

How does Pyrocat work?

Pyrocat works by interacting with a specific molecular target to produce its therapeutic effect.

What is the generic name of Pyrocat?

DIPYROCETYL is the generic (nonproprietary) name of Pyrocat.

What drug class is Pyrocat in?

Pyrocat belongs to the dipyrocetyl class. See all dipyrocetyl drugs at /class/dipyrocetyl.

What development phase is Pyrocat in?

Pyrocat is in Phase 2.

Drug class: All dipyrocetyl drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing